Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

Core Insights - Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing potentially curative therapies for heart disease [1][3] - The company will participate in two upcoming healthcare conferences, showcasing its commitment to advancing its innovative therapies [1][2] Company Overview - Tenaya Therapeutics aims to discover, develop, and deliver therapies targeting the underlying causes of heart disease [3] - The company utilizes integrated capabilities such as target validation, capsid engineering, and manufacturing to create genetic medicines [3] - Tenaya's pipeline includes: - TN-201: Gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) - TN-401: Gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC) - TN-301: Small molecule HDAC6 inhibitor for heart failure with preserved ejection fraction (HFpEF) - Multiple early-stage programs in preclinical development [3]